Using JAK inhibitors to treat Ulcerative Colitis
Influence of JAK Inhibitors on the Disease-associated Network of Intestinal Immune Cells in Ulcerative Colitis
This study is testing if JAK inhibitors can help people with active Ulcerative Colitis by changing their immune response and improving treatment outcomes.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 60 (estimated) |
| Ages | 16 Years to 65 Years |
| Sex | All |
| Sponsor | Leiden University Medical Center Academic / other |
| Locations | 1 site (Leiden, South Holland) |
| Trial ID | NCT05456412 on ClinicalTrials.gov |
What this trial studies
This study investigates the effects of Janus Kinase (JAK) inhibitors on patients with active Ulcerative Colitis (UC). It aims to understand how these treatments alter the composition of immune cells involved in inflammation, which could help identify which patients are likely to respond to therapy. By analyzing the immune response changes, the study seeks to provide insights into the mechanisms of JAK inhibition and improve treatment selection for UC patients. The ultimate goal is to enhance remission rates and reduce the burden of chronic inflammation associated with UC.
Who should consider this trial
Good fit: Ideal candidates for this study are adults with active Ulcerative Colitis.
Not a fit: Patients with inactive Ulcerative Colitis or those who do not have the disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to more effective treatment strategies for patients with Ulcerative Colitis, improving their quality of life.
How similar studies have performed: Other studies have shown promising results with JAK inhibitors in treating inflammatory bowel diseases, indicating potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Age Ulcerative colitis active disease
Where this trial is running
Leiden, South Holland
- Leiden University Medical Center — Leiden, South Holland, Netherlands (Recruiting)
Study contacts
- Principal investigator: Andrea van der Meulen, MD, PhD — Leiden University Medical Center
- Study coordinator: Philip W Voorneveld, MD, PhD
- Email: p.w.voorneveld@lumc.nl
- Phone: +31715296370
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.